Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Immunovia in connection with its rights issue of up to SEK 202 million
Mandate

Vinge is advising Immunovia in connection with its rights issue of up to SEK 202 million

February 20, 2023 Capital Markets and Public M&A

Immunovia AB (publ) is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Immunovia’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård Nevonen, Amanda Knutsson, Anders Sundin Lundberg and Adrian Filipovic.

Related

Vinge has advised Oncopeptides in connection with a directed share issue

 Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

 Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026

Vinge has advised Orexo in connection with its rights issue

 Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026